Quantcast
Home > Quotes > GTHX

G1 Therapeutics, Inc. Common Stock (GTHX) Quote & Summary Data

GTHX 
$41.35
*  
0.46
1.1%
Get GTHX Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading GTHX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
74
Today's High / Low
$ 42.38 / $ 40.90
Share Volume
233,645
50 Day Avg. Daily Volume
388,460
Previous Close
$ 41.81
52 Week High / Low
$ 69.57 / $ 18.035
Market Cap
1,537,601,073
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.53
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.98

Intraday Chart

Shares Traded

Share Volume:
233,645
50 Day Avg. Daily Volume:
388,460

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.53

Trading Range

The current last sale of $41.35 is 129.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 42.38 $ 69.57
 Low: $ 40.90 $ 18.035

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. Our product portfolio is built on a drug discovery platform that targets key cellular pathways with proprietary medicinal chemistry. Our therapies are designed to enable more effective combination treatment strategies and improve outcomes for patients across multiple oncology indications. We were incorporated under the laws of the State of Delaware in May 2008 under the name "G-Zero Therapeutics, Inc." In September 2012, we changed our name to "G1 Therapeutics, Inc." Our principal executive offices are located at 79 T.W. Alexander Drive, 4501 Research Commons, Suite 100, Research Triangle Park, NC 27709, and our telephone number is (919) 213-9835. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.  ... More ...  


Risk Grade

Where does GTHX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 41.40
Open Date:
Nov. 16, 2018
Close Price:
$ 41.81
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x